Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Systemic effects of intravesical atropine sulphate
Autore:
Enskat, R; Deaney, CN; Glickman, S;
Indirizzi:
Univ London Imperial Coll Sci Technol & Med, Sch Med, London, England UnivLondon Imperial Coll Sci Technol & Med London England don, England Kings Coll Hosp NHS Trust, Acad Dept Neurol, London, England Kings Coll Hosp NHS Trust London England d Dept Neurol, London, England Aylesbury Vale Hlthcare, Aylesbury, Bucks, England Aylesbury Vale Hlthcare Aylesbury Bucks England ylesbury, Bucks, England
Titolo Testata:
BJU INTERNATIONAL
fascicolo: 7, volume: 87, anno: 2001,
pagine: 613 - 616
SICI:
1464-4096(200105)87:7<613:SEOIAS>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
URINARY-TRACT DYSFUNCTION; MULTIPLE-SCLEROSIS; SPINA-BIFIDA; BLADDER; SUPPRESSION; TOLTERODINE; CHILDREN;
Keywords:
intravesical; atropine sulphate; detrusor hyper-reflexia; side-effects;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Glickman, S Cent Middlesex Hosp, MS Unit, Acton Lane, London NW10 7NS, England Cent Middlesex Hosp Acton Lane London England NW10 7NS ngland
Citazione:
R. Enskat et al., "Systemic effects of intravesical atropine sulphate", BJU INT, 87(7), 2001, pp. 613-616

Abstract

Objective To investigate systemic antimuscarinic activity after the intravesical administration of hmg of atropine sulphate. Subjects and methods Tell subjects were recruited to an open study in accordance with strict inclusion and exclusion criteria. Each subject received an instillation of 6 mg atropine sulphate diluted to 20 mL with normal saline. All variables were measured at baseline (before instillation) and the instilled solution retained for at least 2 h. After instillation systemic antimuscarinic activity was monitored every 20 min for 2 h then hourly for the next 4 h. The measurements included blood pressure, sublingual temperature. pulse rate, peak expiratory flow rate, lacrimation and salivation rates:all variables were analysed statistically. Facial skin was also observed for hyperaemia. All subjects were questioned about any known symptoms produced by antimuscarinic agents. The heart rate was recorded continuously before and after instillation using a Holter monitor. Results None of the variables changed significantly after instillation andthe Holter analysis showed no relevant variation in heart rate, All subjects consistently denied any antimuscarinic symptoms. One subject had mild cutaneous hyperaemia. as reportedly occurred consistently when her bladder was distended ( > 500 mL). Immediate catheterization drained 600 mL and the hyperaemia resolved. Conclusion The failure to detect systemic antimuscarinic activity at a dose which has previously been shown to suppress detrusor activity suggests that intravesical atropine therapy is safe for further study by clinical trial, and might provide a treatment for detrusor hyper-refexia that is free from side-effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/06/20 alle ore 02:27:09